RGEN — Repligen Income Statement
0.000.00%
Last trade - 00:00
- $6.92bn
- $6.72bn
- $638.76m
- 79
- 12
- 22
- 31
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 270 | 366 | 671 | 802 | 639 |
Cost of Revenue | |||||
Gross Profit | 151 | 210 | 391 | 456 | 315 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 240 | 296 | 503 | 577 | 597 |
Operating Profit | 30.4 | 69.8 | 167 | 225 | 41.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 26.2 | 59.2 | 154 | 219 | 64.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | 21.4 | 59.9 | 128 | 186 | 41.6 |
Net Income Before Extraordinary Items | |||||
Net Income | 21.4 | 59.9 | 128 | 186 | 41.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 21.4 | 59.9 | 128 | 186 | 41.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.77 | 1.58 | 2.46 | 3.53 | 1.6 |